Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone
about
Alemtuzumab for multiple sclerosisAlemtuzumab for multiple sclerosisAlemtuzumab in Multiple Sclerosis: Mechanism of Action and BeyondAlemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Alemtuzumab therapy for multiple sclerosis.Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects.Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid markerThe effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surfaceThe modern management of severe aplastic anaemia.Immunotherapy of rheumatoid arthritis.CAMPATH: from concept to clinic.Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational useGlobal identification of genes and pathways regulated by Akt during activation of T helper cells.Alemtuzumab and multiple sclerosis: therapeutic application.Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.Establishment a CHO Cell Line Expressing Human CD52 Molecule.The immunological function of CD52 and its targeting in organ transplantation.Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes.Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.CD52 expression in non-mycotic T- and NK/T-cell lymphomas.Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.The glycan core of GPI-anchored proteins modulates aerolysin binding but is not sufficient: the polypeptide moiety is required for the toxin-receptor interaction.Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation.Gene expression in the dog epididymis: a model for human epididymal function.
P2860
Q24185899-78E86582-8A55-49E8-A876-3F6B107E9253Q24195076-1C06FF95-3908-4A14-8A30-58F16F48BCCAQ26800128-9A12EB7C-AEC1-4220-86F1-49F27B480A65Q30458930-923ECA34-CF72-436D-9BA0-2363DE7AD207Q33404568-EE3C88CC-8724-41E8-9487-48E8D94647CBQ33407411-1F821FED-2032-400F-A92A-36C65B92905FQ33640235-6C8262A5-5938-4EC4-8F10-3BBFF57A4898Q33933551-F7EAB67C-6E2A-4A6A-8E84-E2744584275FQ33994359-91222FA5-8722-42A6-8D8C-42CDF56EE71CQ35881647-B4B61FCA-CDC4-45DE-AD32-C8A41F1A7E1BQ36251298-8912815F-0A22-4BAF-955A-939965EF7E92Q36768605-B6887D6D-F085-4D35-8E3B-5820D25D099FQ37585261-CDA596F6-4AA2-44D1-9A2E-F1CA5BD4D628Q37679919-6B340E8B-713D-45C7-9D17-FA801BBEF7C2Q37929621-CB91CD9A-A4F8-439A-B492-C6DE0FE1E883Q38722163-CFA9A017-A28F-411B-9C95-35F0C7AEBE9EQ38747419-E15BAFD2-AC41-4443-82BD-1611BC9FDC2DQ39474069-28F5E529-C864-498C-96D2-2F76EC141B26Q39631042-56FA9AAE-57F0-4D13-BE49-CF49AB1ABB3DQ40239088-DED606B3-BC0E-45CC-ABF5-1B5060029BACQ40993369-BCB9D15B-44F8-4EC4-B04A-6451CBDF59BFQ41863626-9BD91908-85E2-41D8-8C9B-40908E87FED5Q42260141-6542CA68-8B6D-4D95-A6EC-B7C1C6113740Q43249169-87940A70-BA2F-4528-92B6-71CBFCA84719Q45711489-D174773F-CBAD-47A1-8445-F04CA22D1EC5Q46375783-7B591733-B86B-431B-8F3E-5495B24B507AQ47290604-26A9BDD0-9639-483C-931A-A22D15F4792BQ48077657-909E890E-5BC7-43F3-92AF-A6D3BA2E492A
P2860
Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone
description
1991 nî lūn-bûn
@nan
1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
name
Characterization of the CAMPAT ...... usually small peptide backbone
@ast
Characterization of the CAMPAT ...... usually small peptide backbone
@en
Characterization of the CAMPAT ...... usually small peptide backbone
@en-gb
Characterization of the CAMPAT ...... usually small peptide backbone
@nl
type
label
Characterization of the CAMPAT ...... usually small peptide backbone
@ast
Characterization of the CAMPAT ...... usually small peptide backbone
@en
Characterization of the CAMPAT ...... usually small peptide backbone
@en-gb
Characterization of the CAMPAT ...... usually small peptide backbone
@nl
prefLabel
Characterization of the CAMPAT ...... usually small peptide backbone
@ast
Characterization of the CAMPAT ...... usually small peptide backbone
@en
Characterization of the CAMPAT ...... usually small peptide backbone
@en-gb
Characterization of the CAMPAT ...... usually small peptide backbone
@nl
P2093
P356
P1476
Characterization of the CAMPAT ...... usually small peptide backbone
@en
P2093
P2860
P304
P356
10.1002/EJI.1830210714
P407
P577
1991-07-01T00:00:00Z